DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $800,371 | +64.9% | 3,226 | +59.5% | 0.24% | +65.7% |
| Q2 2023 | $485,280 | -15.4% | 2,022 | -11.2% | 0.14% | -26.3% |
| Q1 2023 | $573,643 | -9.8% | 2,276 | -5.0% | 0.19% | -15.3% |
| Q4 2022 | $635,946 | -99.9% | 2,396 | +1.9% | 0.23% | -4.6% |
| Q3 2022 | $607,498,000 | +101488.3% | 2,352 | -0.3% | 0.24% | +18.8% |
| Q2 2022 | $598,000 | -7.9% | 2,359 | +6.6% | 0.20% | +14.8% |
| Q1 2022 | $649,000 | -9.1% | 2,212 | +2.0% | 0.18% | +4.1% |
| Q4 2021 | $714,000 | +85.9% | 2,169 | +72.1% | 0.17% | +57.9% |
| Q3 2021 | $384,000 | +10.3% | 1,260 | -2.9% | 0.11% | +10.3% |
| Q2 2021 | $348,000 | +37.5% | 1,298 | +15.4% | 0.10% | +24.4% |
| Q1 2021 | $253,000 | -16.5% | 1,125 | -17.6% | 0.08% | -17.9% |
| Q4 2020 | $303,000 | -32.2% | 1,365 | -34.3% | 0.10% | -44.8% |
| Q3 2020 | $447,000 | +21.8% | 2,078 | 0.0% | 0.17% | +8.9% |
| Q2 2020 | $367,000 | -24.6% | 2,078 | -40.9% | 0.16% | -32.8% |
| Q1 2020 | $487,000 | -24.0% | 3,515 | -15.8% | 0.24% | -14.2% |
| Q4 2019 | $641,000 | +30.3% | 4,175 | +22.6% | 0.27% | +23.4% |
| Q3 2019 | $492,000 | +2.9% | 3,404 | +1.8% | 0.22% | +1.4% |
| Q2 2019 | $478,000 | +54.2% | 3,344 | +42.5% | 0.22% | +48.0% |
| Q1 2019 | $310,000 | +8.8% | 2,347 | -10.4% | 0.15% | +13.0% |
| Q3 2018 | $285,000 | +15.9% | 2,620 | +5.2% | 0.13% | +15.9% |
| Q2 2018 | $246,000 | -89.7% | 2,490 | -89.8% | 0.11% | -90.0% |
| Q1 2018 | $2,385,000 | +1.7% | 24,360 | -3.5% | 1.13% | +11.0% |
| Q4 2017 | $2,344,000 | +10.4% | 25,250 | +2.0% | 1.02% | +1.4% |
| Q3 2017 | $2,123,000 | -12.3% | 24,750 | -13.8% | 1.00% | -12.9% |
| Q2 2017 | $2,422,000 | -15.2% | 28,700 | -14.0% | 1.15% | -11.1% |
| Q1 2017 | $2,856,000 | +0.1% | 33,390 | -8.9% | 1.29% | -11.2% |
| Q4 2016 | $2,853,000 | -1.3% | 36,650 | -0.6% | 1.46% | -13.0% |
| Q3 2016 | $2,890,000 | -21.8% | 36,873 | +0.7% | 1.67% | -29.2% |
| Q2 2016 | $3,697,000 | +2.9% | 36,603 | -3.4% | 2.36% | +11.1% |
| Q1 2016 | $3,594,000 | -6.7% | 37,883 | -8.6% | 2.13% | -4.7% |
| Q4 2015 | $3,851,000 | +11.4% | 41,463 | +2.2% | 2.23% | -12.7% |
| Q3 2015 | $3,457,000 | +13.5% | 40,573 | +13.1% | 2.56% | +14.1% |
| Q1 2015 | $3,046,000 | +4.9% | 35,883 | +5.9% | 2.24% | -0.3% |
| Q4 2014 | $2,905,000 | +5.5% | 33,893 | -6.5% | 2.25% | +11.2% |
| Q3 2014 | $2,753,000 | +488.2% | 36,233 | +509.7% | 2.02% | +243.9% |
| Q2 2014 | $468,000 | -89.3% | 5,943 | -89.9% | 0.59% | -78.5% |
| Q1 2014 | $4,393,000 | +13.6% | 58,573 | +17.0% | 2.73% | +6.1% |
| Q4 2013 | $3,866,000 | – | 50,073 | – | 2.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |